Jon Zugazagoitia

Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy

Yuting Liu, Jon Zugazagoitia, Fahad Shabbir Ahmed et al. · Clinical Cancer Research · 2019 · 337 citations · Full text

Life Sciences, Immunology, Oncology +17

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

Neal Ready, Patrick A. Ott, Matthew D. Hellmann et al. · Journal of Thoracic Oncology · 2019 · 325 citations · Full text

Medicine, Oncology, Pharmacology +8

Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)

S. Cedrés, Santiago Ponce-Aix, Jon Zugazagoitia et al. · PLoS ONE · 2015 · 219 citations · Full text

Medicine, Cancer Biology, Oncology +16

Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling

Jon Zugazagoitia, Swati Gupta, Yuting Liu et al. · Clinical Cancer Research · 2020 · 115 citations · Full text

Medicine, Cancer Biology, Oncology +17

Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials

Alberto Carretero-González, David Lora, Ismael Ghanem et al. · Oncotarget · 2018 · 97 citations · Full text

Medicine, Oncology, Pharmacology +17